Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock investors bought 35,981 call options on the stock. This is an increase of 112% compared to the average daily volume of 16,944 call options.
Institutional Trading of Teva Pharmaceutical Industries
A number of hedge funds have recently bought and sold shares of TEVA. Tobam purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at $25,000. Money Concepts Capital Corp purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its position in Teva Pharmaceutical Industries by 1,729.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock valued at $39,000 after acquiring an additional 3,580 shares during the last quarter. Spire Wealth Management increased its position in Teva Pharmaceutical Industries by 32.7% during the second quarter. Spire Wealth Management now owns 5,584 shares of the company’s stock valued at $42,000 after acquiring an additional 1,375 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after acquiring an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 43.23% of the company’s stock.
Teva Pharmaceutical Industries Trading Down 0.8 %
TEVA stock opened at $11.73 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $7.09 and a 1-year high of $12.21. The business has a fifty day moving average price of $10.62 and a 200-day moving average price of $9.74. The company has a debt-to-equity ratio of 2.46, a quick ratio of 0.65 and a current ratio of 1.00.
Analysts Set New Price Targets
TEVA has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, October 5th. They issued a “buy” rating for the company. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price target for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price target for the stock from $11.00 to $13.00 in a research note on Monday, November 27th. Finally, Piper Sandler raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $8.00 to $12.00 in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.86.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
- Five stocks we like better than Teva Pharmaceutical Industries
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- PulteGroup can set a new high in 2024
- There Are Different Types of Stock To Invest In
- Coinbase stock and the case for 50% upside
- Investing in Commodities: What Are They? How to Invest in Them
- Dollar Tree stock won’t be at a discount for much longer
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.